NEWS COMMENTARY

Scripps Institute launches DETECT, a research study for the rapid detection of viral outbreaks leveraging digital biomarkers

Published:
March 25, 2020
Last Updated:
March 25, 2020
Services:
CPG More...
Priorities:
Consumer Health and Wellness More...
Activities:
Project
by Danielle Bradnan
Very important

The study is not only timely but also groundbreaking in that it is device-agnostic and driving a pool of data notably not siloed by device manufacturers. The study will run for two years, which roughly aligns with projections for vaccine availability for COVID-19, and will be important not only for early front-line detection leading up to a vaccine being available to the public but also for population health management after the current crisis has passed. Clients should be looking to partner with companies running similar studies for digital biomarkers, such as Oura, to play a key role in this evolving global situation and, just as importantly, to keep a relevant place in the healthcare conversation after it is over.

For the original news article, click here .


Further Reading

Human Genomics

Tech Hub | August 25, 2021

The sequencing, analysis, and interpretation of the human genome, which leads to therapeutic, diagnostic, and wellness applications. Not part of subscription

NHS launches world's largest liquid biopsy trial, which could potentially detect 50 types of cancer

News Commentary | September 17, 2021

NHS will use GRAIL's Galleri test in this study, which aims to recruit 140,000 volunteers in eight areas of England. Besides being touted as the world's first and largest clinical trial of its kind, the more important significance of this study is that it is being spearheaded by one of the largest ... Not part of subscription

FDA flags Ellume's recall of its at-home COVID-19 testing kit as the "most serious" type, raising concerns about other similar tests

News Commentary | November 15, 2021

COVID‑19 home tests are becoming the norm in many countries. It is a core technology in the COVID‑19 toolkit for easing restrictions and reopening economies. Hence, when Ellume recalled its COVID‑19 home tests due to high false‑positive rates, there were concerns about other tests on the market. The... Not part of subscription